BlackRock Amends Rigel Pharma Stake (15th Update)
Ticker: RIGL · Form: SC 13G/A · Filed: Jan 25, 2024 · CIK: 1034842
| Field | Detail |
|---|---|
| Company | Rigel Pharmaceuticals Inc (RIGL) |
| Form Type | SC 13G/A |
| Filed Date | Jan 25, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock updated its Rigel Pharma stake, signaling a passive portfolio adjustment.**
AI Summary
BlackRock, Inc. filed an amended SC 13G/A on January 25, 2024, disclosing its ownership of Rigel Pharmaceuticals Inc. common stock as of December 31, 2023. This amendment, the 15th for BlackRock regarding Rigel, indicates a change in their passive investment stake. For investors, this matters because BlackRock is a major institutional investor, and changes in its holdings can signal shifts in confidence or investment strategy for Rigel Pharmaceuticals.
Why It Matters
This filing shows BlackRock's updated passive investment in Rigel Pharmaceuticals, offering insight into a major institutional investor's position, which can influence market perception and trading activity.
Risk Assessment
Risk Level: low — This is a routine amendment by a passive institutional investor and does not indicate any immediate significant risk or opportunity.
Analyst Insight
Investors should note BlackRock's continued passive interest in Rigel Pharmaceuticals, but this filing alone doesn't suggest a strong buy or sell signal. It's a routine update from a large institutional holder.
Key Players & Entities
- BlackRock, Inc. (company) — the reporting person, a major institutional investor
- Rigel Pharmaceuticals Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 25, 2024 (date) — the filing date of the SC 13G/A
- Amendment No: 15 (number) — the number of amendments BlackRock has filed for Rigel Pharmaceuticals Inc.
Forward-Looking Statements
- BlackRock will continue to hold a passive investment in Rigel Pharmaceuticals Inc. (BlackRock, Inc.) — high confidence, target: next 12 months
FAQ
What type of filing is this and who filed it?
This is an SC 13G/A filing, which is an amendment to a Schedule 13G. It was filed by BlackRock, Inc. regarding its holdings in Rigel Pharmaceuticals Inc.
What is the purpose of an SC 13G/A filing?
An SC 13G/A is an amendment to a Schedule 13G, used by passive institutional investors (owning less than 20% of a company's stock) to update their ownership stake in a public company. This specific filing is Amendment No. 15 for BlackRock concerning Rigel Pharmaceuticals Inc.
What is the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' is December 31, 2023, as stated in the filing.
What is the CUSIP Number for Rigel Pharmaceuticals Inc. common stock mentioned in the filing?
The CUSIP Number for Rigel Pharmaceuticals Inc. common stock is 766559603, as specified in the filing.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), indicated by the 'X' in the appropriate box on the cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 25, 2024 regarding RIGEL PHARMACEUTICALS INC (RIGL).